Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 07, 2025 16:30 ET | Source: Oragenics

Oragenics, Inc. Participates in the 3rd Nasal Formulation & Delivery Summit

SARASOTA, Fla., April 07, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a biotechnology company focused on developing novel intranasal therapies for brain-related disorders, today...
March 27, 2025 08:30 ET | Source: Oragenics

Oragenics, Inc. Provides Q1 2025 Shareholder Update on Strategic and Financial Progress

SARASOTA, Fla., March 27, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a biotechnology company focused on developing novel intranasal therapies for brain-related conditions, today...
March 18, 2025 17:33 ET | Source: Oragenics

Oragenics, Inc. Announces Filing of 2024 Annual Report on Form 10-K

SARASOTA, Fla., March 18, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a biotechnology company advancing innovative treatments for concussion and brain-related health conditions,...
March 06, 2025 09:30 ET | Source: Oragenics

Oragenics, Inc. Submits Investigator’s Brochure for Phase II Clinical Trial of ONP-002 in Mild Traumatic Brain Injury (mTBI)

SARASOTA, Fla., March 06, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a biotechnology company advancing innovative treatments for concussion and brain-related health conditions,...
February 25, 2025 08:30 ET | Source: Oragenics

Oragenics, Inc. Chief Medical Officer, Dr. James P. Kelly, to Present at the Emergencies in Medicine Conference on Advancing Concussion Treatment

SARASOTA, Fla., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a biotechnology company advancing innovative treatments for concussion and brain-related health conditions,...
February 24, 2025 08:30 ET | Source: Oragenics

Oragenics, Inc. Chief Medical Officer, Dr. James Kelly, Joins the Medical Board of The Leigh Steinberg Foundation for Concussion, Traumatic Brain Injury, and Brain Health

SARASOTA, Fla., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a biotechnology company advancing innovative treatments for concussion and brain-related health conditions,...
February 11, 2025 08:30 ET | Source: Oragenics

Oragenics, Inc. Announces Partnership with BRAINBox Solutions to Revolutionize Concussion Diagnosis and Treatment

SARASOTA, Fla. and RICHMOND, Va., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a biotechnology company advancing innovative treatments for concussion and brain-related...
February 05, 2025 08:15 ET | Source: Oragenics

Oragenics, Inc. Chief Medical Officer, Dr. James P. Kelly, to Participate in the 12th Annual Brain Health Summit at the Leigh Steinberg Super Bowl Party 2025

SARASOTA, Fla., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a biotechnology company advancing innovative treatments for concussion and brain-related health conditions,...
January 21, 2025 08:15 ET | Source: Oragenics

Oragenics, Inc. Provides Shareholder Update on Strategic Progress and Announces Janet Huffman as Interim CEO

SARASOTA, Fla., Jan. 21, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a biotechnology company advancing innovative treatments for brain-related health conditions, today provided...
December 16, 2024 08:09 ET | Source: Oragenics

Oragenics, Inc. Announces Conversion of Preferred Shares and Elimination of Liquidation Preference

Oragenics, Inc. Announces Conversion of Preferred Shares and Elimination of Liquidation Preference

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right